scPharmaceuticals Inc.

NasdaqGS:SCPH Stock Report

Market Cap: US$304.8m

This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

scPharmaceuticals Future Growth

Future criteria checks 5/6

scPharmaceuticals is forecast to grow earnings and revenue by 70.3% and 34% per annum respectively while EPS is expected to grow by 70.5% per annum.

Key information

70.3%

Earnings growth rate

70.53%

EPS growth rate

Pharmaceuticals earnings growth14.4%
Revenue growth rate34.0%
Future return on equityn/a
Analyst coverage

Low

Last updated07 Oct 2025

Recent future growth updates

Recent updates

scPharmaceuticals Inc. (NASDAQ:SCPH) Soars 26% But It's A Story Of Risk Vs Reward

Jul 19
scPharmaceuticals Inc. (NASDAQ:SCPH) Soars 26% But It's A Story Of Risk Vs Reward

Further Upside For scPharmaceuticals Inc. (NASDAQ:SCPH) Shares Could Introduce Price Risks After 40% Bounce

Jun 02
Further Upside For scPharmaceuticals Inc. (NASDAQ:SCPH) Shares Could Introduce Price Risks After 40% Bounce

Shareholders Will Likely Find scPharmaceuticals Inc.'s (NASDAQ:SCPH) CEO Compensation Acceptable

May 27
Shareholders Will Likely Find scPharmaceuticals Inc.'s (NASDAQ:SCPH) CEO Compensation Acceptable
User avatar

FDA Approval And Medicare Redesign Will Transform CKD Treatment Access

FDA approval of FUROSCIX for CKD patients significantly expands the market, boosting revenue potential and enhancing growth opportunities.

Market Cool On scPharmaceuticals Inc.'s (NASDAQ:SCPH) Revenues Pushing Shares 30% Lower

Apr 04
Market Cool On scPharmaceuticals Inc.'s (NASDAQ:SCPH) Revenues Pushing Shares 30% Lower

scPharmaceuticals Inc. (NASDAQ:SCPH) Shares Slammed 26% But Getting In Cheap Might Be Difficult Regardless

Nov 19
scPharmaceuticals Inc. (NASDAQ:SCPH) Shares Slammed 26% But Getting In Cheap Might Be Difficult Regardless

Downgrade: Here's How Analysts See scPharmaceuticals Inc. (NASDAQ:SCPH) Performing In The Near Term

Nov 18
Downgrade: Here's How Analysts See scPharmaceuticals Inc. (NASDAQ:SCPH) Performing In The Near Term

Is scPharmaceuticals (NASDAQ:SCPH) Using Too Much Debt?

Jun 27
Is scPharmaceuticals (NASDAQ:SCPH) Using Too Much Debt?

scPharmaceuticals Inc. (NASDAQ:SCPH) Stocks Shoot Up 26% But Its P/S Still Looks Reasonable

Jun 27
scPharmaceuticals Inc. (NASDAQ:SCPH) Stocks Shoot Up 26% But Its P/S Still Looks Reasonable

The scPharmaceuticals Inc. (NASDAQ:SCPH) Full-Year Results Are Out And Analysts Have Published New Forecasts

Mar 16
The scPharmaceuticals Inc. (NASDAQ:SCPH) Full-Year Results Are Out And Analysts Have Published New Forecasts

Is scPharmaceuticals (NASDAQ:SCPH) Using Debt Sensibly?

Nov 25
Is scPharmaceuticals (NASDAQ:SCPH) Using Debt Sensibly?

scPharmaceuticals: Furoscix Approval A Potential Paradigm Shift For Heart Failure Patients

Oct 20

FDA approves scPharmaceuticals Furoscix to treat congestion in heart failure

Oct 10

Does scPharmaceuticals (NASDAQ:SCPH) Have A Healthy Balance Sheet?

Jan 11
Does scPharmaceuticals (NASDAQ:SCPH) Have A Healthy Balance Sheet?

Is scPharmaceuticals (NASDAQ:SCPH) A Risky Investment?

Sep 02
Is scPharmaceuticals (NASDAQ:SCPH) A Risky Investment?

scPharmaceuticals: We Still See A High Probability Of Success For FUROSCIX

Aug 26

Earnings and Revenue Growth Forecasts

NasdaqGS:SCPH - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/20271863757294
12/31/2026128-92-74
12/31/202573-60-53-524
6/30/202550-92-66-66N/A
3/31/202542-91-70-70N/A
12/31/202436-85-71-71N/A
9/30/202430-80-71-71N/A
6/30/202424-61-67-67N/A
3/31/202418-58-60-60N/A
12/31/202314-55-59-59N/A
9/30/20237-50-56-56N/A
6/30/20234-45-51-51N/A
3/31/20232-40-44-44N/A
12/31/2022N/A-37-35-35N/A
9/30/2022N/A-35-30-30N/A
6/30/2022N/A-31-27-27N/A
3/31/2022N/A-29-26-26N/A
12/31/2021N/A-28-27-27N/A
9/30/2021N/A-28-29-29N/A
6/30/2021N/A-31-29-29N/A
3/31/2021N/A-32-29-29N/A
12/31/2020N/A-32-28-28N/A
9/30/2020N/A-35-33-33N/A
6/30/2020N/A-32-34-34N/A
3/31/2020N/A-31-32-32N/A
12/31/2019N/A-33-30-30N/A
9/30/2019N/A-27-21-21N/A
6/30/2019N/A-27-21-21N/A
3/31/2019N/A-29N/A-26N/A
12/31/2018N/A-29N/A-29N/A
9/30/2018N/A-31N/A-29N/A
6/30/2018N/A-31N/A-29N/A
3/31/2018N/A-28N/A-27N/A
12/31/2017N/A-24N/A-23N/A
9/30/2017N/A-22N/A-22N/A
6/30/2017N/A-26N/A-20N/A
3/31/2017N/A-24N/A-17N/A
12/31/2016N/A-24N/A-15N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: SCPH is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (3.1%).

Earnings vs Market: SCPH is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: SCPH is expected to become profitable in the next 3 years.

Revenue vs Market: SCPH's revenue (34% per year) is forecast to grow faster than the US market (9.8% per year).

High Growth Revenue: SCPH's revenue (34% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if SCPH's Return on Equity is forecast to be high in 3 years time

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/10/08 15:16
End of Day Share Price 2025/10/06 00:00
Earnings2025/06/30
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

scPharmaceuticals Inc. is covered by 6 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
null nullBMO Capital Markets Equity Research
Gary NachmanBMO Capital Markets Equity Research
Chase KnickerbockerCraig-Hallum Capital Group LLC